Arbutus Biopharma Corporation

NASDAQ:ABUS

3.18 (USD) • At close December 24, 2024
Bedrijfsnaam Arbutus Biopharma Corporation
Symbool ABUS
Munteenheid USD
Prijs 3.18
Beurswaarde 602,584,560
Dividendpercentage 0%
52-weken bereik 2.21 - 4.72
Industrie Biotechnology
Sector Healthcare
CEO Mr. William H. Collier
Website https://www.arbutusbio.com

An error occurred while fetching data.

Over Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits

Vergelijkbare Aandelen

Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc.

OTLK

1.47 USD

Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc.

MNMD

7.32 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

9.87 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

77.58 USD

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

RIGL

16.44 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

5.173 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

62 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.542 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)